bioAffinity Technologies, Inc. (NASDAQ: BIAFW) Stock Competitors & Peer Comparison
See BIAFW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIAFW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIAFW | $0.39 | -26.96% | 12.1M | 1.29 | $0.26 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.70% |
| TMO | $656.58 | -2.98% | 242.8B | 28.35 | $23.16 | +0.28% |
| DHR | $215.61 | -2.53% | 151.5B | 27.01 | $7.98 | +0.70% |
| NTRA | $400.65 | -5.87% | 57.4B | -303.52 | -$1.32 | N/A |
| A | $169.33 | -1.14% | 47.8B | 29.15 | $5.81 | +0.60% |
| WAT | $436.43 | -0.84% | 42.9B | 31.90 | $13.68 | N/A |
| IQV | $259.98 | -2.30% | 42.8B | 21.45 | $12.13 | N/A |
| ILMN | $273.54 | -6.86% | 41.4B | 54.38 | $5.03 | N/A |
| IDXX | $515.41 | -2.21% | 40.7B | 36.25 | $14.22 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
BIAFW vs DHR-PB Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, BIAFW's ROE is -2.57%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, BIAFW is less volatile compared to DHR-PB. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
BIAFW vs TMO Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, TMO has a market cap of 242.8B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while TMO trades at $656.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas TMO's P/E ratio is 28.35. In terms of profitability, BIAFW's ROE is -2.57%, compared to TMO's ROE of +0.13%. Regarding short-term risk, BIAFW is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
BIAFW vs DHR Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, DHR has a market cap of 151.5B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while DHR trades at $215.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas DHR's P/E ratio is 27.01. In terms of profitability, BIAFW's ROE is -2.57%, compared to DHR's ROE of +0.08%. Regarding short-term risk, BIAFW is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
BIAFW vs NTRA Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, NTRA has a market cap of 57.4B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while NTRA trades at $400.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas NTRA's P/E ratio is -303.52. In terms of profitability, BIAFW's ROE is -2.57%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, BIAFW is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
BIAFW vs A Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, A has a market cap of 47.8B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while A trades at $169.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas A's P/E ratio is 29.15. In terms of profitability, BIAFW's ROE is -2.57%, compared to A's ROE of +0.20%. Regarding short-term risk, BIAFW is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check A's competition here
Waters Corporation (NYSE: WAT)
BIAFW vs WAT Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, WAT has a market cap of 42.9B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while WAT trades at $436.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas WAT's P/E ratio is 31.90. In terms of profitability, BIAFW's ROE is -2.57%, compared to WAT's ROE of +0.02%. Regarding short-term risk, BIAFW is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
BIAFW vs IQV Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, IQV has a market cap of 42.8B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while IQV trades at $259.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas IQV's P/E ratio is 21.45. In terms of profitability, BIAFW's ROE is -2.57%, compared to IQV's ROE of +0.22%. Regarding short-term risk, BIAFW is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check IQV's competition here
Illumina, Inc. (NASDAQ: ILMN)
BIAFW vs ILMN Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, ILMN has a market cap of 41.4B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while ILMN trades at $273.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas ILMN's P/E ratio is 54.38. In terms of profitability, BIAFW's ROE is -2.57%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, BIAFW is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check ILMN's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
BIAFW vs IDXX Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, IDXX has a market cap of 40.7B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while IDXX trades at $515.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas IDXX's P/E ratio is 36.25. In terms of profitability, BIAFW's ROE is -2.57%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, BIAFW is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check IDXX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
BIAFW vs MTD Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, MTD has a market cap of 31B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while MTD trades at $1,533.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas MTD's P/E ratio is 35.21. In terms of profitability, BIAFW's ROE is -2.57%, compared to MTD's ROE of -12.00%. Regarding short-term risk, BIAFW is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
BIAFW vs LH Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, LH has a market cap of 25.6B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while LH trades at $311.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas LH's P/E ratio is 18.50. In terms of profitability, BIAFW's ROE is -2.57%, compared to LH's ROE of +0.12%. Regarding short-term risk, BIAFW is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
BIAFW vs DGX Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, DGX has a market cap of 25.2B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while DGX trades at $228.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas DGX's P/E ratio is 22.53. In terms of profitability, BIAFW's ROE is -2.57%, compared to DGX's ROE of +0.14%. Regarding short-term risk, BIAFW is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
BIAFW vs GH Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, GH has a market cap of 22.9B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while GH trades at $170.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas GH's P/E ratio is -48.91. In terms of profitability, BIAFW's ROE is -2.57%, compared to GH's ROE of +2.11%. Regarding short-term risk, BIAFW is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
BIAFW vs EXAS Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas EXAS's P/E ratio is -95.37. In terms of profitability, BIAFW's ROE is -2.57%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, BIAFW is similarly volatile compared to EXAS. This indicates similar risk in terms of short-term price fluctuations for BIAFW.Check EXAS's competition here
Revvity, Inc. (NYSE: RVTY)
BIAFW vs RVTY Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, RVTY has a market cap of 17.1B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while RVTY trades at $153.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas RVTY's P/E ratio is 28.66. In terms of profitability, BIAFW's ROE is -2.57%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, BIAFW is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
BIAFW vs ILMNV Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas ILMNV's P/E ratio is N/A. In terms of profitability, BIAFW's ROE is -2.57%, compared to ILMNV's ROE of N/A. Regarding short-term risk, BIAFW is similarly volatile compared to ILMNV. This indicates similar risk in terms of short-term price fluctuations for BIAFW.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
BIAFW vs MEDP Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, MEDP has a market cap of 16.8B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while MEDP trades at $602.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas MEDP's P/E ratio is 35.34. In terms of profitability, BIAFW's ROE is -2.57%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, BIAFW is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check MEDP's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
BIAFW vs CRL Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, CRL has a market cap of 14.7B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while CRL trades at $304.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas CRL's P/E ratio is 30.81. In terms of profitability, BIAFW's ROE is -2.57%, compared to CRL's ROE of -0.08%. Regarding short-term risk, BIAFW is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check CRL's competition here
PerkinElmer, Inc. (NYSE: PKI)
BIAFW vs PKI Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas PKI's P/E ratio is 41.45. In terms of profitability, BIAFW's ROE is -2.57%, compared to PKI's ROE of +0.03%. Regarding short-term risk, BIAFW is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
BIAFW vs ICLR Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, ICLR has a market cap of 12.4B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while ICLR trades at $161.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas ICLR's P/E ratio is 13.19. In terms of profitability, BIAFW's ROE is -2.57%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, BIAFW is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
BIAFW vs QGEN Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, QGEN has a market cap of 9.4B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while QGEN trades at $45.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas QGEN's P/E ratio is 18.87. In terms of profitability, BIAFW's ROE is -2.57%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, BIAFW is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
BIAFW vs GRAL Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while GRAL trades at $137.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas GRAL's P/E ratio is -14.08. In terms of profitability, BIAFW's ROE is -2.57%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, BIAFW is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
BIAFW vs RDNT Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while RDNT trades at $70.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas RDNT's P/E ratio is 152.78. In terms of profitability, BIAFW's ROE is -2.57%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, BIAFW is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
BIAFW vs SHC Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while SHC trades at $18.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas SHC's P/E ratio is 19.01. In terms of profitability, BIAFW's ROE is -2.57%, compared to SHC's ROE of +0.27%. Regarding short-term risk, BIAFW is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
BIAFW vs BLLN Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, BLLN has a market cap of 4.6B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while BLLN trades at $99.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas BLLN's P/E ratio is 142.72. In terms of profitability, BIAFW's ROE is -2.57%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, BIAFW is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
BIAFW vs SYNH Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas SYNH's P/E ratio is 61.40. In terms of profitability, BIAFW's ROE is -2.57%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, BIAFW is less volatile compared to SYNH. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
BIAFW vs VCYT Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while VCYT trades at $44.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas VCYT's P/E ratio is 22.33. In terms of profitability, BIAFW's ROE is -2.57%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, BIAFW is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
BIAFW vs CDNA Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while CDNA trades at $63.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas CDNA's P/E ratio is 75.94. In terms of profitability, BIAFW's ROE is -2.57%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, BIAFW is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
BIAFW vs OLK Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas OLK's P/E ratio is -96.59. In terms of profitability, BIAFW's ROE is -2.57%, compared to OLK's ROE of -0.07%. Regarding short-term risk, BIAFW is less volatile compared to OLK. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
BIAFW vs WGS Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while WGS trades at $71.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas WGS's P/E ratio is 198.67. In terms of profitability, BIAFW's ROE is -2.57%, compared to WGS's ROE of -0.39%. Regarding short-term risk, BIAFW is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
BIAFW vs PSNL Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while PSNL trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas PSNL's P/E ratio is -14.71. In terms of profitability, BIAFW's ROE is -2.57%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, BIAFW is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
BIAFW vs OPK Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while OPK trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas OPK's P/E ratio is -16.22. In terms of profitability, BIAFW's ROE is -2.57%, compared to OPK's ROE of -0.06%. Regarding short-term risk, BIAFW is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
BIAFW vs CSTL Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while CSTL trades at $33.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas CSTL's P/E ratio is -50.55. In terms of profitability, BIAFW's ROE is -2.57%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, BIAFW is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
BIAFW vs FLGT Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, FLGT has a market cap of 584.5M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while FLGT trades at $20.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas FLGT's P/E ratio is 2058.00. In terms of profitability, BIAFW's ROE is -2.57%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, BIAFW is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
BIAFW vs GRALV Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas GRALV's P/E ratio is N/A. In terms of profitability, BIAFW's ROE is -2.57%, compared to GRALV's ROE of N/A. Regarding short-term risk, BIAFW is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
BIAFW vs NEO Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, NEO has a market cap of 424.1M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while NEO trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas NEO's P/E ratio is 126.96. In terms of profitability, BIAFW's ROE is -2.57%, compared to NEO's ROE of -0.06%. Regarding short-term risk, BIAFW is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
BIAFW vs MYGN Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, MYGN has a market cap of 404.2M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while MYGN trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas MYGN's P/E ratio is -32.92. In terms of profitability, BIAFW's ROE is -2.57%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, BIAFW is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
BIAFW vs CO Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas CO's P/E ratio is 5.06. In terms of profitability, BIAFW's ROE is -2.57%, compared to CO's ROE of +0.11%. Regarding short-term risk, BIAFW is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
BIAFW vs FLDM Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas FLDM's P/E ratio is -4.74. In terms of profitability, BIAFW's ROE is -2.57%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, BIAFW is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
BIAFW vs BDSX Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, BDSX has a market cap of 227.6M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while BDSX trades at $27.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas BDSX's P/E ratio is -8.82. In terms of profitability, BIAFW's ROE is -2.57%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, BIAFW is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
BIAFW vs XGN Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, XGN has a market cap of 197.9M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while XGN trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas XGN's P/E ratio is -10.11. In terms of profitability, BIAFW's ROE is -2.57%, compared to XGN's ROE of -1.22%. Regarding short-term risk, BIAFW is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
BIAFW vs FRNM Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, FRNM has a market cap of 133.5M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while FRNM trades at $16.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas FRNM's P/E ratio is N/A. In terms of profitability, BIAFW's ROE is -2.57%, compared to FRNM's ROE of N/A. Regarding short-term risk, BIAFW is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
BIAFW vs GTH Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas GTH's P/E ratio is -1.11. In terms of profitability, BIAFW's ROE is -2.57%, compared to GTH's ROE of -1.01%. Regarding short-term risk, BIAFW is less volatile compared to GTH. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
BIAFW vs GENE Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas GENE's P/E ratio is -38.25. In terms of profitability, BIAFW's ROE is -2.57%, compared to GENE's ROE of -1.85%. Regarding short-term risk, BIAFW is similarly volatile compared to GENE. This indicates similar risk in terms of short-term price fluctuations for BIAFW.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
BIAFW vs IMDX Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, IMDX has a market cap of 109.1M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while IMDX trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas IMDX's P/E ratio is -2.27. In terms of profitability, BIAFW's ROE is -2.57%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, BIAFW is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
BIAFW vs SERA Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, SERA has a market cap of 78.3M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while SERA trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas SERA's P/E ratio is -3.15. In terms of profitability, BIAFW's ROE is -2.57%, compared to SERA's ROE of -0.47%. Regarding short-term risk, BIAFW is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
BIAFW vs PRPO Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, PRPO has a market cap of 41.8M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while PRPO trades at $23.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas PRPO's P/E ratio is -36.08. In terms of profitability, BIAFW's ROE is -2.57%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, BIAFW is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
BIAFW vs MDXH Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, MDXH has a market cap of 30.8M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while MDXH trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas MDXH's P/E ratio is -0.82. In terms of profitability, BIAFW's ROE is -2.57%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, BIAFW is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
BIAFW vs QUCY Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, QUCY has a market cap of 29.4M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while QUCY trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas QUCY's P/E ratio is -0.06. In terms of profitability, BIAFW's ROE is -2.57%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, BIAFW is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
BIAFW vs AKU Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas AKU's P/E ratio is -0.13. In terms of profitability, BIAFW's ROE is -2.57%, compared to AKU's ROE of -5.32%. Regarding short-term risk, BIAFW is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
BIAFW vs BNR Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, BNR has a market cap of 17.4M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while BNR trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas BNR's P/E ratio is -18.97. In terms of profitability, BIAFW's ROE is -2.57%, compared to BNR's ROE of -0.13%. Regarding short-term risk, BIAFW is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
BIAFW vs CEMI Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas CEMI's P/E ratio is -0.63. In terms of profitability, BIAFW's ROE is -2.57%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, BIAFW is similarly volatile compared to CEMI. This indicates similar risk in terms of short-term price fluctuations for BIAFW.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
BIAFW vs ENZ Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas ENZ's P/E ratio is -2.24. In terms of profitability, BIAFW's ROE is -2.57%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, BIAFW is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
BIAFW vs PMD Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas PMD's P/E ratio is -5.24. In terms of profitability, BIAFW's ROE is -2.57%, compared to PMD's ROE of -0.32%. Regarding short-term risk, BIAFW is similarly volatile compared to PMD. This indicates similar risk in terms of short-term price fluctuations for BIAFW.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
BIAFW vs ME Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas ME's P/E ratio is -0.03. In terms of profitability, BIAFW's ROE is -2.57%, compared to ME's ROE of -3.47%. Regarding short-term risk, BIAFW is similarly volatile compared to ME. This indicates similar risk in terms of short-term price fluctuations for BIAFW.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
BIAFW vs MYNZ Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, BIAFW's ROE is -2.57%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, BIAFW is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
BIAFW vs CHEK Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas CHEK's P/E ratio is -0.43. In terms of profitability, BIAFW's ROE is -2.57%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, BIAFW is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
BIAFW vs CNTG Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas CNTG's P/E ratio is -0.23. In terms of profitability, BIAFW's ROE is -2.57%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, BIAFW is similarly volatile compared to CNTG. This indicates similar risk in terms of short-term price fluctuations for BIAFW.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
BIAFW vs ADVB Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, ADVB has a market cap of 8.8M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while ADVB trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas ADVB's P/E ratio is -58.00. In terms of profitability, BIAFW's ROE is -2.57%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, BIAFW is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
BIAFW vs NDRA Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas NDRA's P/E ratio is -0.90. In terms of profitability, BIAFW's ROE is -2.57%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, BIAFW is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
BIAFW vs APDN Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas APDN's P/E ratio is -0.10. In terms of profitability, BIAFW's ROE is -2.57%, compared to APDN's ROE of -7.23%. Regarding short-term risk, BIAFW is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
BIAFW vs NVTA Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas NVTA's P/E ratio is -0.00. In terms of profitability, BIAFW's ROE is -2.57%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, BIAFW is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
BIAFW vs LMDXW Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, BIAFW's ROE is -2.57%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, BIAFW is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
BIAFW vs LMDX Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas LMDX's P/E ratio is -0.01. In terms of profitability, BIAFW's ROE is -2.57%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, BIAFW is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
BIAFW vs DMTK Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas DMTK's P/E ratio is -0.04. In terms of profitability, BIAFW's ROE is -2.57%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, BIAFW is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
BIAFW vs NOTV Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas NOTV's P/E ratio is -0.03. In terms of profitability, BIAFW's ROE is -2.57%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, BIAFW is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check NOTV's competition here
iSpecimen Inc. (NASDAQ: ISPC)
BIAFW vs ISPC Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, ISPC has a market cap of 2.7M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while ISPC trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas ISPC's P/E ratio is -0.03. In terms of profitability, BIAFW's ROE is -2.57%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, BIAFW is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
BIAFW vs BIAF Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while BIAF trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas BIAF's P/E ratio is -0.71. In terms of profitability, BIAFW's ROE is -2.57%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, BIAFW is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
BIAFW vs SQL Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas SQL's P/E ratio is -0.40. In terms of profitability, BIAFW's ROE is -2.57%, compared to SQL's ROE of -30.46%. Regarding short-term risk, BIAFW is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
BIAFW vs AWH Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas AWH's P/E ratio is -0.09. In terms of profitability, BIAFW's ROE is -2.57%, compared to AWH's ROE of +1.62%. Regarding short-term risk, BIAFW is similarly volatile compared to AWH. This indicates similar risk in terms of short-term price fluctuations for BIAFW.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
BIAFW vs HTGM Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas HTGM's P/E ratio is -0.03. In terms of profitability, BIAFW's ROE is -2.57%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, BIAFW is similarly volatile compared to HTGM. This indicates similar risk in terms of short-term price fluctuations for BIAFW.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
BIAFW vs BIOC Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas BIOC's P/E ratio is -0.01. In terms of profitability, BIAFW's ROE is -2.57%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, BIAFW is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
BIAFW vs SQLLW Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, BIAFW's ROE is -2.57%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, BIAFW is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
BIAFW vs WGSWW Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, BIAFW's ROE is -2.57%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, BIAFW is similarly volatile compared to WGSWW. This indicates similar risk in terms of short-term price fluctuations for BIAFW.Check WGSWW's competition here
Danaher Corporation (NYSE: DHR-PA)
BIAFW vs DHR-PA Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, BIAFW's ROE is -2.57%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, BIAFW is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
BIAFW vs OCDX Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas OCDX's P/E ratio is -42.28. In terms of profitability, BIAFW's ROE is -2.57%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, BIAFW is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check OCDX's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
BIAFW vs MEUSW Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas MEUSW's P/E ratio is N/A. In terms of profitability, BIAFW's ROE is -2.57%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, BIAFW is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
BIAFW vs BNGOW Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas BNGOW's P/E ratio is N/A. In terms of profitability, BIAFW's ROE is -2.57%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, BIAFW is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check BNGOW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
BIAFW vs NDRAW Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas NDRAW's P/E ratio is N/A. In terms of profitability, BIAFW's ROE is -2.57%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, BIAFW is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check NDRAW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
BIAFW vs CHEKZ Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, BIAFW's ROE is -2.57%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, BIAFW is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check CHEKZ's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
BIAFW vs PRXL Comparison October 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAFW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAFW stands at 12.1M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, BIAFW is priced at $0.39 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAFW currently has a P/E ratio of 1.29, whereas PRXL's P/E ratio is 42.97. In terms of profitability, BIAFW's ROE is -2.57%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, BIAFW is less volatile compared to PRXL. This indicates lower risk in terms of short-term price fluctuations for BIAFW.Check PRXL's competition here